Despite all efforts in cancer prevention and significant progress in the availability of new treatment options in the last decade, incidence and global mortality rates are projected to continue to rise.
Our proprietary CELL-THERAPY PLATFORM for silencing intracellular immuno-oncology targets enables RAPID TREATMENT of patients using their own fresh immune cells in an out-patient setting. Once validated in a clinical setting, this novel concept will allow access to and treatment for indications previously not addressable by cell therapy.
Find out more ABOUT US
More about our SCIENCE
is a TUMOR-REACTIVE, autologous cell therapy with a highly specific siRNA-based activation of white blood cells. Currently in clinical Phase 1 testing in patients with various solid tumors.
is a TUMOR-ASSOCIATED cell therapy with a highly specific siRNA-based activation of local immune cells known as Tumor Infiltrating Lymphocytes (TILs). Currently in pre-clinical development.
is a TUMOR-SPECIFIC novel small molecule for immune activation upon oral application. Currently in pre-clinical development.
Learn more about our PIPELINE